Harvard Bioscience, Inc. (HBIO)
Price:
0.44 USD
( + 0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
NovoCure Limited
VALUE SCORE:
3
2nd position
DENTSPLY SIRONA Inc.
VALUE SCORE:
9
The best
Pro-Dex, Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
NEWS
Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
globenewswire.com
2025-09-16 07:00:00HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world's largest and most trusted scientific suppliers.
Harvard Bioscience, Inc. (HBIO) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-11 09:54:25Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants John Duke - President, CEO & Director Mark T. Frost - Interim CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Division Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division Taylor Krafchik - Unidentified Company Operator Good day, and welcome to the Second Quarter 2025 Harvard Bioscience Earnings Conference Call.
Harvard Bioscience Announces Second Quarter 2025 Financial Results
globenewswire.com
2025-08-11 07:00:00Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline New Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2025.
Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET
globenewswire.com
2025-08-04 16:30:00HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m.
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
globenewswire.com
2025-07-17 07:00:00HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will assume the role of President & CEO following the planned retirement of Jim Green, effective July 28, 2025. Jim Green will be retiring from his President, CEO & Chairman roles at Harvard Bioscience after more than 8 years as Chairman and 6 years as President & CEO.
Harvard Bioscience Appoints John Duke to Board of Directors
globenewswire.com
2025-06-02 16:57:00HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company's board of directors.
Harvard Bioscience, Inc. (HBIO) Q1 2025 Earnings Call Transcript
seekingalpha.com
2025-05-12 12:41:40Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q1 2025 Earnings Conference Call May 12, 2025 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller Jim Green - Chairman, President & CEO Mark Frost - Interim CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the First Quarter 2025 Harvard Bioscience Inc Earnings Conference Call. All participants will be in a listen-only mode.
Harvard Bioscience Announces First Quarter 2025 Financial Results
globenewswire.com
2025-05-12 07:00:00HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025.
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET
globenewswire.com
2025-05-05 16:45:00HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Harvard Bioscience Announces CFO Transition
globenewswire.com
2025-04-10 16:45:00HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company's Chief Financial Officer and Treasurer. Ms. Cote's resignation will be effective upon the filing of the Company's Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote's resignation.
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
globenewswire.com
2025-03-12 16:00:00HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025:
Harvard Bioscience, Inc. (HBIO) Q4 2024 Earnings Call Transcript
seekingalpha.com
2025-03-12 11:19:02Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q4 2024 Results Conference Call March 12, 2025 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller Jim Green - Chairman, President & CEO Jennifer Cote - CFO & Treasurer Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Fourth Quarter 2024 Harvard Bioscience Earnings Conference Call. At this time, all participants are in listen-only mode.
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results
globenewswire.com
2025-03-12 07:21:00HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024.
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
globenewswire.com
2025-02-24 16:45:00Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET
globenewswire.com
2025-02-24 11:00:00HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
No data to display
Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
globenewswire.com
2025-09-16 07:00:00HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world's largest and most trusted scientific suppliers.
Harvard Bioscience, Inc. (HBIO) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-11 09:54:25Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants John Duke - President, CEO & Director Mark T. Frost - Interim CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Division Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division Taylor Krafchik - Unidentified Company Operator Good day, and welcome to the Second Quarter 2025 Harvard Bioscience Earnings Conference Call.
Harvard Bioscience Announces Second Quarter 2025 Financial Results
globenewswire.com
2025-08-11 07:00:00Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline New Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2025.
Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET
globenewswire.com
2025-08-04 16:30:00HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m.
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
globenewswire.com
2025-07-17 07:00:00HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will assume the role of President & CEO following the planned retirement of Jim Green, effective July 28, 2025. Jim Green will be retiring from his President, CEO & Chairman roles at Harvard Bioscience after more than 8 years as Chairman and 6 years as President & CEO.
Harvard Bioscience Appoints John Duke to Board of Directors
globenewswire.com
2025-06-02 16:57:00HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company's board of directors.
Harvard Bioscience, Inc. (HBIO) Q1 2025 Earnings Call Transcript
seekingalpha.com
2025-05-12 12:41:40Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q1 2025 Earnings Conference Call May 12, 2025 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller Jim Green - Chairman, President & CEO Mark Frost - Interim CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the First Quarter 2025 Harvard Bioscience Inc Earnings Conference Call. All participants will be in a listen-only mode.
Harvard Bioscience Announces First Quarter 2025 Financial Results
globenewswire.com
2025-05-12 07:00:00HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025.
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET
globenewswire.com
2025-05-05 16:45:00HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Harvard Bioscience Announces CFO Transition
globenewswire.com
2025-04-10 16:45:00HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company's Chief Financial Officer and Treasurer. Ms. Cote's resignation will be effective upon the filing of the Company's Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote's resignation.
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
globenewswire.com
2025-03-12 16:00:00HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025:
Harvard Bioscience, Inc. (HBIO) Q4 2024 Earnings Call Transcript
seekingalpha.com
2025-03-12 11:19:02Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q4 2024 Results Conference Call March 12, 2025 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller Jim Green - Chairman, President & CEO Jennifer Cote - CFO & Treasurer Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Fourth Quarter 2024 Harvard Bioscience Earnings Conference Call. At this time, all participants are in listen-only mode.
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results
globenewswire.com
2025-03-12 07:21:00HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024.
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
globenewswire.com
2025-02-24 16:45:00Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET
globenewswire.com
2025-02-24 11:00:00HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.